

ASSURING THE SAFETY, QUALITY AND EFFICACY OF VETERINARY MEDICINES

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS

NATIONAL PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Bob Martin Flea Tablets 11.4 mg for Cats, Small Dogs and Puppies

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Bob Martin Flea Tablets 11.4mg for Cats, Small Dogs and Puppies
Applicant	Elanco Europe Ltd
	Lilly House
	Priestly Road
	Basingstoke
	Hampshire
	RG24 9NL
Active substance(s)	Nitenpyram
ATC Vetcode	QP52BX02
Target species	Dog and Cat
Indication for use	Treatment of flea infestations (<i>C. felis</i>) on cats and dogs.

The Summary of Product Characteristics (SPC) for this product is available on the Veterinary Medicines Directorate website (<u>www.vmd.defra.gov.uk</u>)

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Informed Consent application in accordance with Article 13c of Directive 2001/82/EC as amended.
	amended.

I. SCIENTIFIC OVERVIEW

The quality / safety / efficacy aspects of this product is/are identical to Capstar 11.4 mg Tablet for Cats and Small Dogs. The initial application for Capstar 11.4 mg Tablet for Cats and Small Dogs was assessed before there was a requirement to have a public assessment report; therefore no details in this section are available.

II. OVERALL CONCLUSION AND BENEFIT- RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)